Abstract
The φC31 integrase system represents a novel technology that opens up new possibilities for gene therapy. The φC31 integrase can integrate introduced plasmid DNA into preferred locations in unmodified mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This review describes the nature of the integration reaction and the genomic integration sites used by the enzyme in human cells. Preclinical applications of the system to gene therapy to date are summarized, including in vivo use in liver, muscle, eye, and joint and ex vivo use in skin keratinocytes, muscle precursor cells, and T cell lines. The safety of this phage integrase system for gene therapy is evaluated, and its strengths and limitations are compared to other gene therapy approaches. Ongoing and planned improvements to the phage integrase system are discussed. We conclude that gene therapy strategies using φC31 integrase and its derivatives offer great promise for success in the near term.
Keywords: att site, genetic disease, genomic integration, liver, non-viral, phage, serine recombinase, site-specific
Current Gene Therapy
Title: The φC31 Integrase System for Gene Therapy
Volume: 6 Issue: 6
Author(s): Michele P. Calos
Affiliation:
Keywords: att site, genetic disease, genomic integration, liver, non-viral, phage, serine recombinase, site-specific
Abstract: The φC31 integrase system represents a novel technology that opens up new possibilities for gene therapy. The φC31 integrase can integrate introduced plasmid DNA into preferred locations in unmodified mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This review describes the nature of the integration reaction and the genomic integration sites used by the enzyme in human cells. Preclinical applications of the system to gene therapy to date are summarized, including in vivo use in liver, muscle, eye, and joint and ex vivo use in skin keratinocytes, muscle precursor cells, and T cell lines. The safety of this phage integrase system for gene therapy is evaluated, and its strengths and limitations are compared to other gene therapy approaches. Ongoing and planned improvements to the phage integrase system are discussed. We conclude that gene therapy strategies using φC31 integrase and its derivatives offer great promise for success in the near term.
Export Options
About this article
Cite this article as:
Calos P. Michele, The φC31 Integrase System for Gene Therapy, Current Gene Therapy 2006; 6 (6) . https://dx.doi.org/10.2174/156652306779010642
DOI https://dx.doi.org/10.2174/156652306779010642 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Molecular Markers for Individualized Therapy in Colorectal Cancer: Progress Towards a Pharmacogenomics Array
Current Pharmacogenomics and Personalized Medicine Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Identification of Novel 5,6-Dimethoxyindan-1-one Derivatives as Antiviral Agents
Medicinal Chemistry Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets Peroxynitrite-Mediated Structural Changes in Histone H2A: Biochemical and Biophysical Analysis
Protein & Peptide Letters Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine In Silico Design, Synthesis and Bioactivity of N-(2, 4-Dinitrophenyl)-3-oxo- 3-phenyl-N-(aryl) Phenyl Propanamide Derivatives as Breast Cancer Inhibitors
Current Computer-Aided Drug Design A Review on Corrosion Protection of Iron and Steel
Recent Patents on Corrosion Science Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Nanomagnets-From Fundamental Physics to Biomedicine
Current Nanoscience Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Anti-Cancer Agents in Medicinal Chemistry Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology The Basement Membrane Zone in Asthma
Current Respiratory Medicine Reviews Inhibition of Matrix Metalloproteinases as a Feasible Therapeutic Target in Rheumatoid Arthritis
Current Rheumatology Reviews Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease
Current Neuropharmacology Current Hot Potatoes in Atrial Fibrillation Ablation
Current Cardiology Reviews